Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2022 / Jan / Introducing “SynTOF” – and Its Potential Impact on Alzheimer’s
Mass Spectrometry

Introducing “SynTOF” – and Its Potential Impact on Alzheimer’s

How a flow cytometry and time-of-flight mass spectrometry mashup helps explore risk factors of neurodegenerative diseases

By Margot Lespade 01/17/2022 1 min read

Share

A recently developed technique, dubbed synaptometry by time-of-flight (SynTOF), combines flow cytometry with time-of-flight mass spectrometry, allowing scientists to examine tens of millions of individual human single-synapse events using 38 antibody probes (1). Specifically, the technique allowed Stanford University researchers to compare and contrast human brains without pathologic change or with pure Alzheimer’s disease (AD) or Lewy body disease (LBD).
 

By applying machine-learning approaches to the dataset, the technique not only confirmed pre-established differences, such as reduced caudate dopamine transporter in LBD and increased hippocampal pathologic tau in AD, but also offered new insights; for example, increased hippocampal CD47 and lowered DJI proteins in AD, and higher ApoE proteins in AD with dementia. 

Given that next-best alternatives for such analyses – namely, array tomography and conventional flow cytometry – hit a ceiling of one million single-synapse events, SynTOF represents “an unparalleled opportunity for multiplex analysis,” according to the researchers.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. T Phongpreecha et al., Science Advances (2021). DOI: 10.1126/sciadv.abk0473.

About the Author(s)

Margot Lespade

More Articles by Margot Lespade

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.